Drug Shortage Report for NALOXONE HYDROCHLORIDE INJECTION USP
| Report ID | 210664 |
| Drug Identification Number | 02382482 |
| Brand name | NALOXONE HYDROCHLORIDE INJECTION USP |
| Common or Proper name | NALOXONE HYDROCHLORIDE INJECTION USP |
| Company Name | HIKMA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | NALOXONE HYDROCHLORIDE |
| Strength(s) | 0.4MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 1mL |
| ATC code | V03AB |
| ATC description | ALL OTHER THERAPEUTIC PRODUCTS |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2023-11-17 |
| Actual start date | |
| Estimated end date | 2025-06-30 |
| Actual end date | 2025-08-07 |
| Shortage status | Resolved |
| Updated date | 2025-08-18 |
| Company comments | Hikma NALOXONE INJECTABLE (DIN 02458578, product code 0141AA01) available in same size ampoule and strength. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 55 STANDISH COURT, SUITE 1050 MISSISSAUGA, ONTARIO CANADA L5R 0G3 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2023-11-17 | English | Compare |